Lottery winner plans to give cash to help one particular group of people in NC
'I want to help the homeless people in my community,' Robert Lowman told lottery officials.
Lowman paid $5 for a 20X The Cash ticket on Sunday, April 13, and it won him $250,000. That's the top prize in the game and the odds of winning it are 1 in 1,335,942. He bought the ticket at the J & H Mart in Wilson.
'It's a miracle,' Lowman said in a news release. 'I really didn't know what to do or what to think.'
He picked up his money Monday, April 14, at lottery headquarters in Raleigh, and the prize came to $179,376 after state and federal withholdings, lottery officials said.
'In addition to helping the homeless, he plans to do some work on his apartment,' officials said.
Lowman lives in Wilson, about a 50-mile drive east from Raleigh, and he didn't go into details of how or when he'll start helping the community's less fortunate.
Wilson County had nearly 17% of its population 'living with severe housing problems' in 2023, Data USA reported. Meanwhile, homelessness in the state 'rose 19% from 2023 to 2024,' according to the N.C. Housing Coalition.
The 20X The Cash game debuted in February 2024 with 10 top prizes of $250,000 and 'Lowman won the last top prize.'
'The lottery will begin the process of ending the game,' officials said.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Miami Herald
an hour ago
- Miami Herald
Longtime electrician hits jackpot in NC. The lottery prize left him ‘shaking'
A longtime electrician hit the jackpot — and now, he plans to save for retirement. 'I couldn't believe it,' winner Rudolph Ruggiero Jr. told the North Carolina Education Lottery. 'I was shaking.' Ruggiero won $435,915 after stopping at a Harris Teeter grocery store in Greensboro. While there, he tried his luck on the Carolina Cash 5 game, lottery officials wrote in an Aug. 20 news release. It turns out, the man's $1 ticket held a big surprise. It beat 1-in-962,598 odds to match all the numbers picked in the Aug. 13 drawing. 'I thought maybe I won a couple thousand dollars or something,' Ruggiero said. But he didn't realize his ticket was worth much more. He was at a lottery claim center when a worker checked his numbers, revealing the jackpot win. 'The most I've won before this is 50 bucks,' said Ruggiero, a Greensboro resident. The winner, who has worked as an electrician for five decades, kept $312,770 after taxes. In addition to planning for retirement, he hopes to deposit some of his prize money into the bank. It's not the first time someone with a long career has bought a lucky lottery ticket. A North Carolina teacher of more than 30 years wanted to put aside money for retirement after his life-changing win, McClatchy News reported in March.
Yahoo
a day ago
- Yahoo
3 Reasons to Sell JJSF and 1 Stock to Buy Instead
Over the past six months, J&J Snack Foods's stock price fell to $112.72. Shareholders have lost 9.7% of their capital, which is disappointing considering the S&P 500 has climbed by 5%. This may have investors wondering how to approach the situation. Is now the time to buy J&J Snack Foods, or should you be careful about including it in your portfolio? Dive into our full research report to see our analyst team's opinion, it's free. Why Is J&J Snack Foods Not Exciting? Despite the more favorable entry price, we don't have much confidence in J&J Snack Foods. Here are three reasons why there are better opportunities than JJSF and a stock we'd rather own. 1. Fewer Distribution Channels Limit its Ceiling With $1.6 billion in revenue over the past 12 months, J&J Snack Foods is a small consumer staples company, which sometimes brings disadvantages compared to larger competitors benefiting from economies of scale and negotiating leverage with retailers. On the bright side, it can grow faster because it has a longer list of untapped store chains to sell into. 2. Projected Revenue Growth Is Slim Forecasted revenues by Wall Street analysts signal a company's potential. Predictions may not always be accurate, but accelerating growth typically boosts valuation multiples and stock prices while slowing growth does the opposite. Over the next 12 months, sell-side analysts expect J&J Snack Foods's revenue to rise by 2.2%, a deceleration versus This projection is underwhelming and indicates its products will see some demand headwinds. 3. Free Cash Flow Margin Dropping If you've followed StockStory for a while, you know we emphasize free cash flow. Why, you ask? We believe that in the end, cash is king, and you can't use accounting profits to pay the bills. As you can see below, J&J Snack Foods's margin dropped by 2.7 percentage points over the last year. If its declines continue, it could signal increasing investment needs and capital intensity. J&J Snack Foods's free cash flow margin for the trailing 12 months was 4.2%. Final Judgment J&J Snack Foods isn't a terrible business, but it isn't one of our picks. After the recent drawdown, the stock trades at 21.2× forward P/E (or $112.72 per share). This valuation tells us it's a bit of a market darling with a lot of good news priced in - you can find more timely opportunities elsewhere. We'd suggest looking at an all-weather company that owns household favorite Taco Bell. Stocks We Like More Than J&J Snack Foods Trump's April 2025 tariff bombshell triggered a massive market selloff, but stocks have since staged an impressive recovery, leaving those who panic sold on the sidelines. Take advantage of the rebound by checking out our Top 5 Growth Stocks for this month. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025). Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+354% five-year return). Find your next big winner with StockStory today. StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
3 days ago
- Yahoo
Massive Headwinds Are on the Horizon for Pharmaceutical Stocks, but Here Are 2 That Could Weather the Storm
Key Points Johnson & Johnson and Novartis are facing (or will soon face) important patent cliffs. Both companies can handle these challenges thanks to their deep lineups and innovative abilities. Both drugmakers also have excellent dividend-paying stocks. 10 stocks we like better than Johnson & Johnson › Pharmaceutical companies regularly encounter substantial headwinds. Among the most significant are patent cliffs -- when therapies lose patent exclusivity, inviting cheaper generic or biosimilar competition that erodes their market share. Although these sometimes threaten drugmakers, some can effectively handle the challenge and perform relatively well. With that as a backdrop, let's discuss two pharmaceutical leaders that have faced (or will face) patent expiration for some of their most important products, but should be able to overcome the threat: Johnson & Johnson (NYSE: JNJ) and Novartis (NYSE: NVS). 1. Johnson & Johnson In July 2024, Johnson & Johnson began facing biosimilar competition for Stelara, an immunology medicine and one of its best-selling products, in Europe. The same thing occurred in the U.S. in February of this year. The result is that Stelara's sales are dropping off a cliff. In the second quarter, the medicine generated revenue of $1.7 billion -- a 42.7% decrease from the same period last year. Still, Johnson & Johnson continues to post solid financial results. Its top line in the period grew by 5.8% year over year to $23.7 billion. J&J even raised both top- and bottom-line guidance for the year. In other words, the company is performing relatively well, despite the drop in sales for Stelara. J&J has an incredibly diversified business with a long list of medicines in its pharmaceutical segment. Some of its top growth drivers include cancer medicines Darzalex and Erleada, as well as Remicade, which treats several immunology conditions. The company also has newer products in its arsenal: Imaavy for myasthenia gravis (a condition that causes muscle weakness) was approved earlier this year, and it's awaiting word from regulators for TAR-200, a highly promising investigational medicine for bladder cancer. Furthermore, Johnson & Johnson is a leading player in the medical device industry. One long-term growth driver for the company could be its robotic-assisted surgery system, the Ottava, which is still undergoing clinical trials in the U.S. J&J can overcome patent cliffs -- and, for that matter, drug-price negotiations that also threaten its business -- through innovation. That's what the company is doing with Stelara, and it can do so in the future. Finally, Johnson & Johnson is a terrific dividend stock; it's raised its payouts for 62 consecutive years, making it a Dividend King. The company can handle all the challenges it faces and still deliver solid returns over the long run. 2. Novartis Novartis is gearing up for generic competition for Entresto, a medication for heart failure, later this year in the U.S. Through the first half of the year, this drug generated $4.6 billion in sales, almost 52% of which came from the U.S. With cheaper generics in its single most important market for its best-selling medicine, Novartis might be in trouble -- except it isn't. The drugmaker continues to expect high-single-digit revenue growth for the year, a strong performance for a pharmaceutical giant. Even if Entresto's patent cliff has a greater impact on financial results next year, the company should be fine. Novartis has a vast and diversified portfolio of medicines across various therapeutic areas. Many of its products are blockbusters; seven had already generated more than $1 billion in revenue each through the first six months of 2025. Novartis also has several newer products that will help drive top-line growth for a long time. For instance, in April the company earned U.S. approval for Vanrafia, a medicine indicated to treat proteinuria (excess protein in urine) in patients with a rare kidney disease called IgA nephropathy. Some analysts estimate that Vanrafia could hit peak sales of $1.5 billion. Novartis' extensive lineup, combined with its continued launches of new products, should help it move beyond Entresto's patent cliff. Additionally, the company is engaged in patent litigation over the legitimacy of generic versions of Entresto. If it ends up winning these battles, it might be owed money from companies that would have launched those generics on the market. Even if that doesn't happen, the drugmaker should continue delivering consistent revenue and earnings over the long run, as well as annual dividend increases. The company has raised its payouts for 28 consecutive years. Despite the patent-cliff threat it faces, Novartis remains a top pick for those seeking blue chip dividend stocks. Should you invest $1,000 in Johnson & Johnson right now? Before you buy stock in Johnson & Johnson, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Johnson & Johnson wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $668,155!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,106,071!* Now, it's worth noting Stock Advisor's total average return is 1,070% — a market-crushing outperformance compared to 184% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 13, 2025 Prosper Junior Bakiny has positions in Johnson & Johnson. The Motley Fool recommends Johnson & Johnson. The Motley Fool has a disclosure policy. Massive Headwinds Are on the Horizon for Pharmaceutical Stocks, but Here Are 2 That Could Weather the Storm was originally published by The Motley Fool
